Skip Navigation



NDT Plus Advance Access published online on December 4, 2008
NDT Plus, doi:10.1093/ndtplus/sfn188
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2/1/27    most recent
sfn188v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by de Oliveira, R. A.
Right arrow Articles by Andrade, L.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Electrolyte disturbances and acute kidney injury induced by imatinib therapy

Rodrigo Azevedo de Oliveira, Igor Denizarde Bacelar Marques, Antonio Carlos Seguro and Lúcia Andrade

Department of Nephrology, University of São Paulo School of Medicine, São Paulo, Brazil

Correspondence: Lúcia Andrade, Laboratório de Pesquisa Básica LIM-12, Faculdade de Medicina da USP, Av. Dr. Arnaldo 455, sala 3310, CEP 01246-903, São Paulo, SP, Brazil. Tel: +55-011-3066-7281/3066-7292; Fax: +55-11-3088-2267; E-mail: luciacan{at}usp.br


  Abstract

Imatinib mesylate is an anticancer agent that selectively inhibits protein kinases involved in the pathophysiology of cancer. It is now the first-line therapy for patients with chronic myeloid leukaemia (CML) and is generally well tolerated. Here, we describe a case of a patient receiving imatinib for CML. The patient developed renal failure accompanied by severe hypophosphataemia, hypokalaemia and hypomagnesaemia. We discuss the pathophysiological characteristics of imatinib-induced renal injury, and we demonstrate that these electrolyte disturbances were caused by increased urinary excretion of phosphate and potassium. Early diagnosis and correction of imatinib-induced renal injury and electrolyte disorders can improve clinical outcomes.

Key Words: acute kidney injury • hypokalaemia • hypophosphataemia • imatinib

Received for publication October 24, 2008. Accepted for publication November 4, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.